

Impact of Tuberculosis on Maternal and Fetal Health

Alexandre Kirby*

Department of Microbiology, University Hospital of Nice, France

Abstract

Tuberculosis (TB) is a persistent global health concern that can have profound implications for both maternal and fetal health during pregnancy. The physiological changes that occur during pregnancy can complicate the diagnosis and management of TB in expectant mothers. Maternal TB can lead to adverse outcomes such as preterm labor, low birth weight, and maternal mortality. Moreover, the impact of TB on fetal health is increasingly recognized, with risks of intrauterine growth restriction, congenital TB, and stillbirth. This article explores the multifaceted impact of TB on maternal and fetal health, highlighting the challenges of diagnosis and treatment in pregnant women. It underscores the necessity of integrated care approaches involving both obstetric and pulmonary specialties, as well as strategies for prevention and early detection to minimize the detrimental effects of TB on this vulnerable population.

Keywords: Tuberculosis; Maternal health; Fetal health; Pregnancy; Prenatal care; Diagnosis

Introduction

Tuberculosis (TB) remains a global public health challenge, affecting millions of people every year. While TB primarily affects the lungs, it can also impact other parts of the body, leading to severe health complications. Among the vulnerable populations, pregnant women are at an increased risk of experiencing adverse effects of TB due to the physiological changes that occur during pregnancy. This article delves into the impact of tuberculosis on maternal and fetal health, highlighting the challenges and considerations in managing this dual health concern [1].

Since the prevalence of TB affects a large number of young adults, the same age group constitutes the largest number of patients infected with human immunodeficiency virus (HIV), specifically, the 15-49-year-old age group. The interaction between these 2 diseases poses a 2-fold problem: the unusual extrapulmonary manifestations that are more likely to occur in this population present a diagnostic challenge and, with the high prevalence of drug resistance, important considerations must be addressed when selecting therapy [2].

Maternal health impact

Pregnant women with TB face a unique set of challenges. The physiological changes that accompany pregnancy, such as hormonal fluctuations and changes in lung capacity, can exacerbate the symptoms of TB. Common symptoms of TB, including persistent cough, fatigue, and night sweats, can be misconstrued as typical discomforts of pregnancy, leading to delayed diagnosis and treatment initiation.

Furthermore, TB during pregnancy can lead to more severe complications, such as preterm labor, low birth weight, and maternal mortality. The disease can weaken the immune system, making pregnant women more susceptible to other infections, thereby increasing the risk of complications. TB-associated respiratory issues can strain the cardiovascular system, posing risks to both the mother and the developing fetus [3, 4].

Fetal health impact

The impact of maternal TB on fetal health is a growing concern. Studies have shown that TB infection during pregnancy can result in adverse outcomes for the fetus. The placental barrier does not always prevent the transmission of *Mycobacterium tuberculosis* to the fetus. This can lead to intrauterine growth restriction, congenital TB, and

even stillbirth. Additionally, the stress and inflammation caused by maternal TB can disrupt the placental function, affecting the exchange of nutrients and oxygen between the mother and the fetus [5].

Management challenges

Diagnosing TB in pregnant women can be complex due to overlapping symptoms and the need to consider the safety of both the mother and the fetus during diagnostic procedures. Radiological examinations like X-rays and certain medications used for TB treatment, such as isoniazid, can raise concerns about potential harm to the fetus. This requires a delicate balance between providing adequate care for the mother and protecting the developing fetus.

Considerations for treatment

The management of TB in pregnant women involves careful considerations. Multidrug therapy, a standard treatment for TB, should be administered with the utmost caution [6, 7]. Healthcare providers must weigh the benefits of treatment against potential risks to the fetus. Collaboration between obstetricians and pulmonologists is essential to develop a tailored treatment plan that minimizes harm to both the mother and the unborn child.

Prevention and education

Preventing maternal TB is crucial for safeguarding maternal and fetal health. TB screening should be integrated into routine prenatal care, especially in areas with a high prevalence of the disease. Additionally, raising awareness among pregnant women and healthcare providers about the signs, symptoms, and risks of TB can lead to early detection and timely intervention [8, 9].

*Corresponding author: Alexandre Kirby, Department of Microbiology, University Hospital of Nice, France, E-mail: kirby.alex23@ac.fr

Received: 03-Aug-2023, Manuscript No: awbd-23-110753, **Editor assigned:** 05-Aug-2023, PreQC No: awbd-23-110753 (PQ), **Reviewed:** 19-Aug-2023, QC No: awbd-23-110753, **Revised:** 25-Aug-2023, Manuscript No: awbd-23-110753 (R), **Published:** 31-Aug-2023, DOI: 10.4172/2167-7719.1000197

Citation: Kirby A (2023) Impact of Tuberculosis on Maternal and Fetal Health. Air Water Borne Dis 12: 197.

Copyright: © 2023 Kirby A. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Discussion

The impact of tuberculosis on maternal and fetal health is a complex interplay of physiological, diagnostic, and therapeutic challenges. The physiological changes that occur during pregnancy can complicate the presentation and diagnosis of tuberculosis in pregnant women, often leading to delayed identification and treatment. The overlap between common symptoms of tuberculosis and pregnancy discomforts can further hinder early intervention. This emphasizes the need for heightened awareness among both healthcare providers and expectant mothers to ensure timely diagnosis and appropriate care [10].

Maternal tuberculosis not only poses risks to the mother's health but also has far-reaching consequences for fetal well-being. The placental barrier, while effective at times, cannot entirely prevent the transmission of *Mycobacterium tuberculosis* to the developing fetus. This can result in a spectrum of adverse fetal outcomes, from intrauterine growth restriction to congenital TB and even stillbirth. The physiological stress induced by maternal TB, coupled with potential disruptions in placental function, underscores the intricate relationship between maternal infection and fetal development [11].

Treatment of tuberculosis in pregnant women demands a delicate balance between effective management of the disease and safeguarding the health of both the mother and the fetus. The standard multidrug therapy regimen used for TB treatment necessitates careful consideration of potential risks and benefits. Collaborative efforts between obstetricians and pulmonologists are essential to formulate tailored treatment plans that minimize harm while optimizing the chances of recovery for both maternal and fetal health.

Conclusion

The impact of tuberculosis on maternal and fetal health is a multifaceted challenge that requires a comprehensive approach. Timely diagnosis, collaboration between medical specialties, and patient education are key factors in mitigating the adverse effects of TB on pregnant women and their unborn children. By addressing the unique challenges posed by TB during pregnancy, we can strive to ensure the well-being of both mothers and their precious infants. A synergistic collaboration between healthcare providers from various specialties is crucial to navigate the intricacies of maternal TB and ensure the best possible outcomes for both mother and child. Furthermore, ongoing research to better understand the interactions

between TB infection, pregnancy, and fetal development is imperative to develop more effective prevention and treatment strategies in this unique population. Ultimately, by addressing the intricate relationship between tuberculosis and pregnancy, we can strive to mitigate its impact on maternal and fetal health and improve the prospects of a healthy outcome for both generations.

Acknowledgement

None

Conflict of Interest

None

References

1. Mourad A, Baker AW, Stout JE (2021) Reduction in expected survival associated with nontuberculous mycobacterial pulmonary disease. *Clin. Infect. Dis.* 72: 552-555.
2. Ji LC, Chen S, Piao W, Hong CY, Li J L, et al. (2022) Increasing trends and species diversity of nontuberculous mycobacteria in a coastal migrant City-Shenzhen, China. *Biomed Environ Sci* 35: 146 -150.
3. Blomgran R, Desvignes L, Briken V (2021) *Mycobacterium tuberculosis* inhibits neutrophil apoptosis, leading to delayed activation of naive CD4 T cells. *Cell Host Microbe* 11: 81-90
4. Cohen NB, Gern MN, Delahaye JN (2018) Alveolar macrophages provide an early *Mycobacterium tuberculosis* niche and initiate dissemination. *Cell Host Microbe* 24: 439-446.
5. Corleis B, Dorhoi A (2019) Early dynamics of innate immunity during pulmonary tuberculosis. *Immunol Lett* 221: 56-60.
6. Gannon AD, Darch SE (2021) Same game, different players: Emerging pathogens of the CF lung. *mBio* 12: 01217- 01220.
7. Pavlik I, Ulmann V, Falkinham JO (2022) Nontuberculous Mycobacteria (2022). *Ecology and Impact on Animal and Human Health. Microorganisms*10: 1516.
8. Baptista P, Gola A, Huang Y (2019) The chemoattractant receptor Ebi2 drives intranodal naive CD4(+) T cell peripheralization to promote effective adaptive immunity. *Immunity* 50: 1188-1201.
9. Ernst JN (2012) The immunological life cycle of tuberculosis. *Nat Rev Immunol* 12: 581-591.
10. Eum J, Kong K, Hong MS, Hong M (2010) Neutrophils are the predominant infected phagocytic cells in the airways of patients with active pulmonary. *TB Chest* 137: 122-128.
11. Blomgran F, Desvignes K, Briken P (2021) *Mycobacterium tuberculosis* inhibits neutrophil apoptosis leading to delayed activation of naive CD4 T cells. *Cell Host Microbe* 11: 81-90.